:: CLDF ::

Experimental Pharmacological Agents for the Treatment of Primary Biliary Cholangitis

J Exp Pharmacol. 2020 Dec 17;12:643-652. doi: 10.2147/JEP.S267375.eCollection 2020.

Annarosa Floreani^1 2

Obeticholic acid is associated with improvements in AST-to-platelet ratio index and GLOBE score in patients with primary biliary cholangitis

JHEP Rep. 2020 Sep 29;3(1):100191. doi: 10.1016/j.jhepr.2020.100191. eCollection 2021 Feb.

Maren H Harms¹, Gideon M Hirschfield², Annarosa Floreani³, Marlyn J Mayo⁴, Albert Parés⁵, Alexander Liberman⁶, Elizabeth Smoot Malecha⁶, Richard Pencek⁶, Leigh MacConell⁶, Bettina E Hansen^2 7

Primary biliary cholangitis

Lancet. 2020 Dec 12;396(10266):1915-1926. doi: 10.1016/S0140-6736(20)31607-X.

Ana Lleo¹, Giu-Qiang Wang², Merrill Eric Gershwin³, Gideon M Hirschfield⁴

Portal hypertension in primary biliary cholangitis: prevalence, natural history and histological correlates

Eur J Gastroenterol Hepatol. 2020 Dec 14. doi: 10.1097/MEG.0000000000002033.Online ahead of print.

Thomas W Warnes¹, Stephen A Roberts², Alexander Smith¹, Victor M Cope³, Patricia Vales⁴, Najib Y Haboubi⁵, Raymond F McMahon⁶

UDCA Decreases Incidence of Primary Biliary Cholangitis and Biliary Complications after Liver Transplant: A Meta-Analysis

Liver Transpl. 2020 Nov 13. doi: 10.1002/lt.25935. Online ahead of print.

Mark R Pedersen¹, Garrett Greenan², Sumant Arora³, Arvind Murali³, Marlyn J Mayo¹

Primary Sclerosing Cholangitis and Primary Biliary Cirrhosis Overlap Syndrome: A Review

J Clin Transl Hepatol. 2020 Sep 28;8(3):336-346. doi: 10.14218/JCTH.2020.00036.Epub 2020 Aug 24.

Sheena Mago¹, George Y Wu¹

Fibrates for itch (FITCH) in fibrosing cholangiopathies: a double blind, randomized, placebo-controlled trial

Gastroenterology. 2020 Oct 5;S0016-5085(20)35226-4. doi:10.1053/j.gastro.2020.10.001.Online ahead of print.

Elsemieke de Vries¹, Ruth Bolier¹, Jorn Goet², Albert Parés³, Jef Verbeek⁴, Marleen de Vree⁵, Joost Drenth⁶, Karel van Erpecum⁷, Karin van Nieuwkerk⁸, Frans van der Heide⁵, Nahid Mostafavi¹, Jeltje Helder¹, Cyriel Ponsioen¹, Ronald Oude Elferink¹, Henk van Buuren², Ulrich Beuers⁹, Netherlands Association for the Study of the Liver - Cholestasis Working Group

Genome-wide resolution peripheral blood methylome profiling reveals signatures for cholestatic liver disease

Epigenomics. 2020 Aug;12(16):1363-1375. doi: 10.2217/epi-2020-0048. Epub 2020 Sep 11.

Raymond M Moore¹, Zhifu Sun¹, Brian D Juran², Konstantinos N Lazaridis²

A placebo-controlled randomised trial of budesonide for primary biliary cholangitis following an insufficient response to UDCA

J Hepatol. 2020 Sep 17;S0168-8278(20)33623-0. doi: 10.1016/j.jhep.2020.09.011.Online ahead of print.

G M Hirschfield¹, U Beuers², L Kupcinskas³, P Ott⁴, A Bergquist⁵, M Färkkilä⁶, M P Manns⁷, A Parés⁸, U Spengler⁹, M Stiess¹⁰, R Greinwald¹⁰, M Pröls¹⁰, D Wendum¹¹, U Drebber¹², R Poupon¹³

10.

Liver Stiffness Measured by Either Magnetic Resonance or Transient Elastography Is Associated With Liver Fibrosis and Is an Independent Predictor of Outcomes Among Patients With Primary Biliary Cholangitis

J Clin Gastroenterol. 2020 Sep 23. doi: 10.1097/MCG.0000000000001433. Online ahead of print.

Karim T Osman¹, Daniel B Maselli¹, Ilkay S Idilman², Daniel J Rowan³, Jason K Viehman⁴, William S Harmsen⁴, Denise M Harnois⁵, Elizabeth J Carey⁶, Andrea A Gossard¹, Nicholas F LaRusso¹, Keith D Lindor⁶, Sudhakar K Venkatesh², John E Eaton¹

11.

An update on the management of cholestatic liver diseases

Clin Med (Lond). 2020 Sep;20(5):513-516. doi: 10.7861/clinmed.2020-0697.

Gautham Appanna¹, Yiannis Kallis²

12.

Review article: pathophysiology and management of primary biliary cholangitis

Aliment Pharmacol Ther. 2020 Aug 19. doi: 10.1111/apt.16023. Online ahead of print.

Kristel K Leung^1 2, Maya Deeb^1 2, Gideon M Hirschfield^1 2

13.

Prevalence and long-term outcome of sub-clinical primary sclerosing cholangitis in patients with ulcerative colitis

Liver Int. 2020 Aug 25. doi: 10.1111/liv.14645. Online ahead of print.

Emma L Culver¹, Helen K Bungay², Margaret Betts², Colm Forde^2 3, Otto Buchel⁴, Charis Manganis¹, Bryan F Warren⁵, Jr Fraser Cummings^1 6, Satish Keshav¹, Simon P L Travis¹, Roger W Chapman¹

14.

Role of Antinuclear Antibodies in Primary Biliary Cholangitis

Am J Gastroenterol. 2020 Jul 22. doi: 10.14309/ajg.0000000000000765. Online ahead of print.

Cynthia Levy¹, Christopher L Bowlus²

15.

Reevaluating Goals of Therapy in Primary Biliary Cholangitis: Is Good Enough Is Not Good Enough Anymore?

Am J Gastroenterol. 2020 Jul;115(7):1024-1025. doi: 10.14309/ajg.0000000000000693.

Richard J Bower¹, Catherine Frenette²

16.

Cholangiocarcinoma: Diagnosis and Management

Clin Liver Dis. 2020 Aug;24(3):421-436. doi: 10.1016/j.cld.2020.04.005.Epub 2020 May 29.

Adam P Buckholz¹, Robert S Brown Jr²

17.

Gut microbiome in primary sclerosing cholangitis: A review

World J Gastroentero. 2020 Jun 7;26(21):2768-2780.doi: 10.3748/wjg.v26.i21.2768.

Rebecca Little¹, Eytan Wine², Binita M Kamath¹, Anne M Griffiths¹, Amanda Ricciuto³

18.

How Much Liver Tissue Is Required for Sufficient Histological Staging in Patients With Primary Biliary Cholangitis?

Digestion. 2020 Jun 3;1-9. doi: 10.1159/000507392. Online ahead of print.

Marcel Vetter¹, Andreas E Kremer¹, Abbas Agaimy², Lukas Pfeifer¹, Markus F Neurath¹, Jürgen Siebler¹, Steffen Zopf^3 4

19.

Effects of Primary Biliary Cholangitis on Quality of Life and Health Care Costs in the United Kingdom

Clin Gastroenterol Hepatol. 2020 Jun 17;S1542-3565(20)30836-3.doi: 10.1016/j.cgh.2020.06.025. Online ahead of print.

Stephen Rice¹, Viviana Albani², Dimitrios Minos³, Gulnar Fattakhova², George F Mells⁴, Marco Carbone⁴, Steven Flack⁴, Nikoletta Varvaropoulou⁴, Jonathan Badrock⁴, Ann Spicer⁴, Richard N Sandford⁴, Mark D F Shirley⁵, Diarmuid Coughlan², Gideon Hirschfield⁶, Simon D Taylor-Robinson⁷, UK-PBC Consortium; Luke Vale², David E J Jones⁸

20.

Risk Factors for Complications After Cholecystectomy for Common Bile Duct Stones: An EAST Multicenter Study

Surgery. 2020 Jul;168(1):62-66. doi: 10.1016/j.surg.2020.04.011. Epub 2020 May 26.

Brett M Tracy¹, Cameron W Paterson², Denise M Torres³, Katelyn Young³, Beth R Hochman⁴, Martin D Zielinski⁵, Sigrid K Burruss⁶, Michelle B Mulder⁷, Daniel Dante Yeh⁷, Rondi B Gelbard², EAST Retained Common Bile Duct Stones Study Group

EAST Retained Common Bile Duct Stones Study Group:

Beth Hochman, Natasha Coleman, Anna Goldenberg-Sandau, Jennifer Schweinsburg, Rondi Gelbard, Cameron Paterson, Brett Tracy, Rondi Gelbard, Cameron Paterson, Brett Tracy, Katelyn Young, Denise Torres, David Morris, Ashley Boyer, Sigrid Burruss, Xian Luo-Owen, Daniel Cullinane, Laura Cullinane, April Mendoza, Apostolos Gaitanidis, Martin Zielinski, Maraya Camazine, Shaneeta Johnson, Michelle Mulder, Rishi Rattan, D Dante Yeh, Jonathan Saxe, Daniel Kinstedt, Amanda Celii, Kiran Venincasa

21.

Obeticholic Acid-A New Therapy in PBC and NASH

B Med Bull. 2020 May 15;133(1):95-104. doi: 10.1093/bmb/ldaa006.

Roger W Chapman^1 2, Kate D Lynch^1 2 3 4

22.

Reevaluating Goals of Therapy in Primary Biliary Cholangitis: Is Good Enough Is Not Good Enough Anymore?

Am J Gastroenterol. 2020 May 20. doi: 10.14309/ajg.0000000000000693. Online ahead of print.

Richard J Bower¹, Catherine Frenette²

23.

Emerging Drugs for the Treatment of Primary Biliary Cholangitis

Expert Opin Emerg Drugs. 2020 Jun;25(2):101-112. doi: 10.1080/14728214.2020.1751814.Epub 2020 May 5.

Naw April Phaw^1 2, Jessica Katharine Dyson^1 2, David Jones^1 2 3

24.

Pregnancy Outcomes in Women With Primary Biliary Cholangitis and Primary Sclerosing Cholangitis: A Retrospective Cohort Study

BJOG. 2020 Jun;127(7):876-884. doi: 10.1111/1471-0528.16119. Epub 2020 Mar 8.

M Cauldwell¹, F L Mackie², P J Steer¹, M A Henehghan³, J H Baalman⁴, J Brennand⁵, T Johnston², S Dockree⁶, C Hedley⁷, S Jarvis⁸, S Khan⁹, F M McAuliffe⁴, L Mackillop⁶, L Penna⁷, B Smith¹⁰, P Trivedi⁹, S Verma^11 12, R Westbrook¹³, S Winifield¹⁴, C Williamson¹⁵

25.

Osteoporosis in Primary Biliary Cholangitis: Prevalence, Impact and Management Challenges

Clin Exp Gastroenterol. 2020 Jan 15;13:17-24. doi: 10.2147/CEG.S204638.eCollection 2020.

Hirsh D Trivedi¹, Christopher J Danford¹, Daniela Goyes¹, Alan Bonder¹

26.

Goals of Treatment for Improved Survival in Primary Biliary Cholangitis: Treatment Target Should Be Bilirubin Within the Normal Range and Normalization of Alkaline Phosphatase

Am J Gastroenterol. 2020 Feb 20. doi: 10.14309/ajg.0000000000000557. Online ahead of print.

Carla F Murillo Perez^1 2, Maren H Harms², Keith D Lindor³, Henk R van Buuren², Gideon M Hirschfield¹, Christophe Corpechot⁴, Adriaan J van der Meer², Jordan J Feld¹, Aliya Gulamhusein¹, Willem J Lammers², Cyriel Y Ponsioen⁵, Marco Carbone⁶, Andrew L Mason⁷, Marlyn J Mayo⁸, Pietro Invernizzi⁶, Pier Maria Battezzati⁹, Annarosa Floreani¹⁰, Ana Lleo¹¹, Frederik Nevens¹², Kris V Kowdley¹³, Tony Bruns^14 15, George N Dalekos¹⁶, Nikolaos K Gatselis¹⁶, Douglas Thorburn¹⁷, Palak J Trivedi¹⁸, Xavier Verhelst¹⁹, Albert Parés²⁰, Harry L A Janssen¹, Bettina E Hansen^1 21, GLOBAL PBC Study Group

27.

A Clinical Review of Primary Biliary Cholangitis

Gastroenterol Nurs. Mar/Apr 2020;43(2):E48-E55. doi: 10.1097/SGA.0000000000000480.

Richard Pullen¹

28.

Ursodeoxycholic Acid Treatment Preferentially Improves Overall Survival Among African Americans With Primary Biliary Cholangitis

Am J Gastroenterol. 2020 Feb;115(2):262-270. doi: 10.14309/ajg.0000000000000512.

Stuart C Gordon¹, Kuan-Han Hank Wu², Keith Lindor³, Christopher L Bowlus⁴, Carla V Rodriguez^5 6, Heather Anderson⁷, Joseph A Boscarino⁸, Sheri Trudeau², Loralee B Rupp⁹, Irina V Haller¹⁰, Robert J Romanelli¹¹, Jeffrey J VanWormer¹², Mark A Schmidt¹³, Yihe G Daida¹⁴, Amandeep Sahota¹⁵, Jennifer Vincent¹⁶, Talan Zhang¹, Jia Li¹, Mei Lu¹, FOLD Investigators

29.

Diagnosis and Management of Primary Biliary Cholangitis

Am J Gastroenterol. 2019 Jan;114(1):48-63. doi: 10.1038/s41395-018-0390-3.

Zobair M Younossi¹, David Bernstein², Mitchell L Shiffman³, Paul Kwo⁴, W Ray Kim⁵, Kris V Kowdley⁶, Ira M Jacobson⁷

30.

Characteristics and Outcomes of Liver Transplantation for Primary Biliary Cholangitis in Young Patients: Analysis of the United Network for Organ Sharing Database

Transplantation. 2019 Jun;103(6):1191-1198. doi: 10.1097/TP.0000000000002501.

Amandeep Singh¹, Danielle Fritze², Mahsa Mansouri³, Rocio Lopez⁴, Fred Poordad^2 3, Eric Lawitz^2 3, Francisco Cigarroa², Glen Halff², Naim Alkhouri³

31.

Pruritus Is Common and Undertreated in Patients With Primary Biliary Cholangitis in the United Kingdom

Clin Gastroenterol Hepatol. 2019 Jun;17(7):1379-1387.e3. doi: 10.1016/j.cgh.2018.12.007.Epub 2018 Dec 14.

Vinod S Hegade¹, George F Mells², Holly Fisher³, Stuart Kendrick⁴, Julia DiBello⁵, Kim Gilchrist⁵, Graeme J Alexander², Gideon M Hirschfield⁶, Richard N Sandford⁷, David E J Jones⁸, UK-PBC Consortium

32.

Effects of Age and Sex of Response to Ursodeoxycholic Acid and Transplant-free Survival in Patients With Primary Biliary Cholangitis

Gastroenterol Hepatol. 2019 Sep;17(10):2076-2084.e2. doi: 10.1016/j.cgh.2018.12.028.Epub 2019 Jan 4.

Angela C Cheung¹, Willem J Lammers², Carla F Murillo Perez³, Henk R van Buuren², Aliya Gulamhusein³, Palak J Trivedi⁴, Konstantinos N Lazaridis¹, Cyriel Y Ponsioen⁵, Annarosa Floreani⁶, Gideon M Hirschfield³, Christophe Corpechot⁷, Marlyn J Mayo⁸, Pietro Invernizzi⁹, Pier Maria Battezzati¹⁰, Albert Parés¹¹, Frederik Nevens¹², Douglas Thorburn¹³, Andrew L Mason¹⁴, Marco Carbone⁹, Kris V Kowdley¹⁵, Tony Bruns¹⁶, George N Dalekos¹⁷, Nikolaos K Gatselis¹⁷, Xavier Verhelst¹⁸, Keith D Lindor¹⁹, Ana Lleo⁹, Raoul Poupon⁷, Harry L A Janssen³, Bettina E Hansen²⁰, Global PBC Study Group

33.

Primary Biliary Cholangitis in Medicare Population: The Impact on Mortality and Resource Use

Hepatology. 2019 Jan;69(1):237-244. doi: 10.1002/hep.30174.

Mehmet Sayiner^1 2, Pegah Golabi¹, Maria Stepanova³, Issah Younossi³, Fatema Nader³, Andrei Racila^2 3, Zobair M Younossi^1 2

34.	Primary Biliary Cholangitis in Medicare Population: The Impact on Mortality and Resource Utilization
	Sayiner M¹,², Golabi P¹, Stepanova M³, Younossi I³, Nader F³, Racila A²,³, Younossi ZM¹,². Hepatology. 2018 Jul 17. doi: 10.1002/hep.30174. [Epub ahead of print]

35.	Alcohol and Obesity: A Dangerous Association for Fatty Liver Disease
	Mahli A1, Hellerbrand C. Dig Dis. 2016;34 Suppl 1:32-9. doi: 10.1159/000447279. Epub 2016 Aug 22.

36.	Discrimination of Nonalcoholic Steatohepatitis Using Transient Elastography in Patients with Nonalcoholic Fatty Liver Disease
	Lee HW1, Park SY2, Kim SU1, Jang JY3, Park H4, Kim JK1, Lee CK5, Chon YE1, Han KH1. PLoS One. 2016 Jun 10;11(6):e0157358. doi: 10.1371/journal.pone.0157358. eCollection 2016.

37.	Formulation for Effective Screening and Management of Nonalcoholic Steatohepatitis: Noninvasive NAFLD Management Strategy
	Hirose K1, Kanefuji T2, Suda T2, Sugitani S3, Nagasaki K4, Kubota T5, Igarashi M1, Terai S1. Gastroenterol Res Pract. 2016;2016:6343656. doi: 10.1155/2016/6343656. Epub 2016 Jun 13.

38.	The impact of body weight gain on nonalcoholic fatty liver disease and metabolic syndrome during earlier and later adulthood
	Du S1, Wang C2, Jiang W3, Li C4, Li Y1, Feng R5, Sun C6. Diabetes Res Clin Pract. 2016 Jun;116:183-91. doi: 10.1016/j.diabres.2016.04.047. Epub 2016 Apr 30.

39.	The Association between Non-Invasive Hepatic Fibrosis Markers and Cardiometabolic Risk Factors in the Framingham Heart Study
	Long MT1,2, Pedley A2,3, Massaro JM2,4, Hoffmann U5, Fox CS2,6. PLoS One. 2016 Jun 24;11(6):e0157517. doi: 10.1371/journal.pone.0157517. eCollection 2016.

40.	Nonalcoholic fatty liver disease and obstructive sleep apnea
	Aron-Wisnewsky J1, Clement K2, Pépin JL3. Metabolism. 2016 Aug;65(8):1124-35. doi: 10.1016/j.metabol.2016.05.004. Epub 2016 May 13.

41.	Host factors are dominant in the development of post-liver transplant non-alcoholic steatohepatitis
	Boga S1, Munoz-Abraham AS1, Rodriguez-Davalos MI1, Emre SH1, Jain D1, Schilsky ML1. World J Hepatol. 2016 May 28;8(15):659-64. doi: 10.4254/wjh.v8.i15.659.

42.	Non-alcoholic fatty liver disease and dyslipidemia: An update
	Katsiki N1, Mikhailidis DP2, Mantzoros CS3.Author information Metabolism. 2016 May 13. pii: S0026-0495(16)30018-X. doi: 10.1016/j.metabol.2016.05.003. [Epub ahead of print]

43.	The Natural Course of Non-Alcoholic Fatty Liver Disease
	Calzadilla Bertot L1, Adams LA2,3. Int J Mol Sci. 2016 May 20;17(5). pii: E774. doi: 10.3390/ijms17050774.

44.	Lifestyle and Dietary Interventions in the Management of Nonalcoholic Fatty Liver Disease
	Hannah WN Jr1, Harrison SA2. Dig Dis Sci. 2016 May;61(5):1365-74. doi: 10.1007/s10620-016-4153-y.

45.	Gut Microbiota and Lifestyle Interventions in NAFLD
	Houghton D1, Stewart CJ2, Day CP3,4, Trenell M5. Int J Mol Sci. 2016 Mar 25;17(4). pii: E447. doi: 10.3390/ijms17040447.

46.	A Comprehensive Updated Review of Pharmaceutical and Nonpharmaceutical Treatment for NAFLD
	Hossain N1, Kanwar P1, Mohanty SR1. Gastroenterol Res Pract. 2016;2016:7109270. doi: 10.1155/2016/7109270. Epub 2016 Feb 23.

47.	Fibrosis Assessment in Nonalcoholic Fatty Liver Disease (NAFLD) in 2016
	Kaswala DH1, Lai M1, Afdhal NH2. Dig Dis Sci. 2016 May;61(5):1356-64. doi: 10.1007/s10620-016-4079-4. Epub 2016 Mar 26.

48.	Type 2 Diabetes in Non-Alcoholic Fatty Liver Disease and Hepatitis C Virus Infection-Liver: The
	Ballestri S1, Nascimbeni F2,3, Romagnoli D4, Baldelli E5, Targher G6, Lonardo A7. Int J Mol Sci. 2016 Mar 9;17(3). pii: E355. doi: 10.3390/ijms17030355.

49.	Biopsy and Noninvasive Methods to Assess Progression of Nonalcoholic Fatty Liver Disease
	Bedossa P1, Patel K2. Gastroenterology. 2016 Mar 19. pii: S0016-5085(16)00354-1. doi: 10.1053/j.gastro.2016.03.008. [Epub ahead of print]

50.	Telomeres, NAFLD and Chronic Liver Disease
	Donati B1, Valenti L2. Int J Mol Sci. 2016 Mar 15;17(3). pii: E383. doi: 10.3390/ijms17030383.

51.	Non-alcoholic fatty liver disease and liver transplantation
	Khan RS1, Newsome PN2. Metabolism. 2016 Mar 3. pii: S0026-0495(16)00052-4. doi: 10.1016/j.metabol.2016.02.013. [Epub ahead of print]

52.	Perspectives on Treatment for Nonalcoholic Steatohepatitis
	Lassailly G1, Caiazzo R2, Pattou F2, Mathurin P3. Gastroenterology. 2016 Mar 10. pii: S0016-5085(16)00323-1. doi: 10.1053/j.gastro.2016.03.004. [Epub ahead of print]

53.	Comparison of Doppler ultrasound and transient elastography in the diagnosis of significant fibrosis in patients with nonalcoholic steatohepatitis
	Ergelen R1, Yilmaz Y2, Asedov R3, Celikel C4, Akin H2, Bugdayci O3, Altun E5, Tuney D3. Abdom Radiol (NY). 2016 Mar 10. [Epub ahead of print]

54.	Metabolic Impact of Nonalcoholic Steatohepatitis in Obese Patients With Type 2 Diabetes
	Lomonaco R1, Bril F2, Portillo-Sanchez P2, Ortiz-Lopez C3, Orsak B3, Biernacki D2, Lo M4, Suman A5, Weber MH6, Cusi K7. Diabetes Care. 2016 Feb 9. pii: dc151876. [Epub ahead of print]

55.	Cost-Effectiveness Analysis: Risk Stratification of Nonalcoholic Fatty Liver Disease (NAFLD) by the Primary Care Physician Using the NAFLD Fibrosis Score
	Tapper EB1, Hunink MG2,3, Afdhal NH1, Lai M1, Sengupta N4. PLoS One. 2016 Feb 23;11(2):e0147237. doi: 10.1371/journal.pone.0147237. eCollection 2016.

56.	Histamine H2-Receptor Antagonist Use Is Associated With Lower Prevalence of Nonalcoholic Fatty Liver Disease: A Population-based Study From the National Health and Nutrition Examination Survey, 2001-2006
	Shen H1, Liangpunsakul S. J Clin Gastroenterol. 2016 Feb 22. [Epub ahead of print]

57.	Steatohepatitis and liver fibrosis are predicted by the characteristics of very low density lipoprotein in nonalcoholic fatty liver disease
	Jiang ZG1, Tapper EB1, Connelly MA2, Pimentel CM1, Feldbrügge L1, Kim M3, Krawczyk S3, Afdh Al N1, Robson SC1, Herman M3, Otvos JD2, Mukamal KJ4, Lai M1. Liver Int. 2016 Jan 27. doi: 10.1111/liv.13076. [Epub ahead of print]

58.	Screening for Nonalcoholic Steatohepatitis in Individuals with Type 2 Diabetes: A Cost-Effectiveness Analysis
	Corey KE1,2, Klebanoff MJ3,4, Tramontano AC5, Chung RT6,7, Hur C8,9,10. Dig Dis Sci. 2016 Jan 29. [Epub ahead of print]

59.	Nonalcoholic Steatohepatitis: Diagnostic Challenges
	Gill RM1, Kakar S2. Surg Pathol Clin. 2013 Jun;6(2):227-57. doi: 10.1016/j.path.2013.03.002. Epub 2013 May 4.

60.	Is There Any Relation between the Degree of Fatty Liver Disease and Severity of Lower Urinary Tract Symptoms?
	Song YA1, Kwon SS2, Doo SW3, Kim JH4, Yang WJ3, Song YS3. Urology. 2015 Dec 9. pii: S0090-4295(15)01099-7. doi: 10.1016/j.urology.2015.11.030. [Epub ahead of print]

61.	Circulating microRNAs in nonalcoholic fatty liver disease
	DiStefano JK1, Gerhard GS2. Expert Rev Gastroenterol Hepatol. 2015 Nov 25. [Epub ahead of print]

62.	Clinical patterns of hepatocellular carcinoma (hcc) in non alcoholic fatty liver disease (NAFLD): A multicenter prospective study
	Piscaglia F1, Svegliati-Baroni G2, Barchetti A3, Pecorelli A1, Marinelli S1, Tiribelli C3,4, Bellentani S3; HCC-NAFLD Italian Study group. Hepatology. 2015 Nov 24. doi: 10.1002/hep.28368. [Epub ahead of print]

63.	Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study
	Armstrong MJ1, Gaunt P2, Aithal GP3, Barton D4, Hull D4, Parker R1, Hazlehurst JM5, Guo K4; LEAN trial team, Abouda G6, Aldersley MA7, Stocken D8, Gough SC5, Tomlinson JW5, Brown RM9, Hübscher SG10, Newsome PN11. Lancet. 2015 Nov 19. pii: S0140-6736(15)00803-X. doi: 10.1016/S0140-6736(15)00803-X. [Epub ahead of print]

64.	Non-alcoholic fatty liver disease and risk of cardiovascular disease
	Lonardo A1, Sookoian S2, Pirola CJ3, Targher G4. Metabolism. 2015 Sep 25. pii: S0026-0495(15)00271-1. doi: 10.1016/j.metabol.2015.09.017. [Epub ahead of print]

65.	Dietary approach in the treatment of nonalcoholic fatty liver disease
	Ferolla SM1, Silva LC1, Ferrari Mde L1, da Cunha AS1, Martins Fdos S1, Couto CA1, Ferrari TC1. World J Hepatol. 2015 Oct 28;7(24):2522-34. doi: 10.4254/wjh.v7.i24.2522.

66.	The Prevalence of Non-Alcoholic Fatty Liver Disease in Children and Adolescents: A Systematic Review and Meta-Analysis
	Anderson EL1, Howe LD1, Jones HE2, Higgins JP3, Lawlor DA1, Fraser A1. PLoS One. 2015 Oct 29;10(10):e0140908. doi: 10.1371/journal.pone.0140908. eCollection 2015.

67.	Non-alcoholic Steatohepatitis is Associated with Increased Mortality in Obese Patients Undergoing Bariatric Surgery
	Goossens N1, Hoshida Y2, Song WM3, Jung M4, Morel P4, Nakagawa S5, Zhang B3, Frossard JL6, Spahr L6, Friedman SL5, Negro F7, Rubbia-Brandt L8, Giostra E6. Clin Gastroenterol Hepatol. 2015 Oct 19. pii: S1542-3565(15)01406-8. doi: 10.1016/j.cgh.2015.10.010. [Epub ahead of print]

68.	Nonalcoholic Steatohepatitis is the Most Rapidly Growing Indication for Simultaneous Liver Kidney Transplantation in the United States
	Singal AK1, Hasanin M, Kaif M, Wiesner R, Kuo YF. Transplantation. 2015 Oct 16. [Epub ahead of print]

69.	Omega-3 fatty acids: Mechanisms of benefit and therapeutic effects in pediatric and adult NAFLD
	Nobili V1, Alisi A2, Musso G3, Scorletti E4,5, Calder PC4,5, Byrne CD4,5. Crit Rev Clin Lab Sci. 2015 Oct 14:1-15. [Epub ahead of print]

70.	Systematic review of genetic association studies involving histologically confirmed non-alcoholic fatty liver disease
	Wood KL1, Miller MH2, Dillon JF2. BMJ Open Gastroenterol. 2015 Feb 17;2(1):e000019. doi: 10.1136/bmjgast-2014-000019. eCollection 2015.

71.	Sex-specific differences in hepatic fat oxidation and synthesis may explain the higher propensity for NAFLD in men
	Pramfalk C1, Pavlides M2,3, Banerjee R2, McNeil CA1, Neubauer S2, Karpe F1,4, Hodson L1. J Clin Endocrinol Metab. 2015 Sep 28:jc20152649. [Epub ahead of print]

72.	Hype or Reality: Should Patients with Metabolic Syndrome-related NAFLD be on the Hunter-Gatherer (Paleo) Diet to Decrease Morbidity?
	Tarantino G1, Citro V2, Finelli C3. J Gastrointestin Liver Dis. 2015 Sep;24(3):359-68. doi: 10.15403/jgld.2014.1121.243.gta.

73.	Nonalcoholic fatty liver disease: Current status and future directions
	Demir M1, Lang S1, Steffen HM1. J Dig Dis. 2015 Sep 25. doi: 10.1111/1751-2980.12291. [Epub ahead of print]

74.	Nonalcoholic Fatty Liver Disease and Fibrosis in Youth Taking Psychotropic Medications: Literature Review, Case Reports, and Management
	Gracious BL1,2, Bhatt R2,3, Potter C4. J Child Adolesc Psychopharmacol. 2015 Oct 8. [Epub ahead of print]

75.	Relevance of low testosterone to non-alcoholic fatty liver disease
	Mody A1, White D2, Kanwal F3, Garcia JM4. Cardiovasc Endocrinol. 2015 Sep 1;4(3):83-89.

76.	The Gut Microbiota and Nonalcoholic Fatty Liver Disease
	Quigley EM1, Monsour HP1. Semin Liver Dis. 2015 Aug;35(3):262-9. doi: 10.1055/s-0035-1562946. Epub 2015 Sep 17.

77.	Systemic Complications of Nonalcoholic Fatty Liver Disease: When the Liver Is Not an Innocent Bystander
	Vanni E1, Marengo A1, Mezzabotta L1, Bugianesi E1. Semin Liver Dis. 2015 Aug;35(3):236-49. doi: 10.1055/s-0035-1562944. Epub 2015 Sep 17.

78.	Hepatic Injury in Nonalcoholic Steatohepatitis Contributes to Altered Intestinal Permeability
	Luther J1, Garber JJ1, Khalili H1, Dave M2, Bale SS3, Jindal R3, Motola DL1, Luther S1, Bohr S3, Jeoung SW1, Deshpande V1, Singh G4, Turner JR4, Yarmush ML3, Chung RT1, Patel SJ3. Cell Mol Gastroenterol Hepatol. 2015 Mar;1(2):222-232.

79.	Relevance of low testosterone to non-alcoholic fatty liver disease
	Mody A1, White D2, Kanwal F3, Garcia JM4. Cardiovasc Endocrinol. 2015 Sep 1;4(3):83-89.

80.	The Gut Microbiota and Nonalcoholic Fatty Liver Disease
	Quigley EM1, Monsour HP1. Semin Liver Dis. 2015 Aug;35(3):262-9. doi: 10.1055/s-0035-1562946. Epub 2015 Sep 17.

81.	Systemic Complications of Nonalcoholic Fatty Liver Disease: When the Liver Is Not an Innocent Bystander
	Vanni E1, Marengo A1, Mezzabotta L1, Bugianesi E1. Semin Liver Dis. 2015 Aug;35(3):236-49. doi: 10.1055/s-0035-1562944. Epub 2015 Sep 17.

82.	Hepatic Injury in Nonalcoholic Steatohepatitis Contributes to Altered Intestinal Permeability
	Luther J1, Garber JJ1, Khalili H1, Dave M2, Bale SS3, Jindal R3, Motola DL1, Luther S1, Bohr S3, Jeoung SW1, Deshpande V1, Singh G4, Turner JR4, Yarmush ML3, Chung RT1, Patel SJ3. Cell Mol Gastroenterol Hepatol. 2015 Mar;1(2):222-232.

83.	The Prevalence and Presumed Etiology of Elevated Aminotransferase Levels in a Pacific Northwest Tribal Community
	Scott J, Kowdley KV, Ioannou GN, Krantz E, Lallemand O, Tsosie U, Buchwald D. J Health Care Poor Underserved. 2015;26(3):957-66. doi: 10.1353/hpu.2015.0091.

84.	Burden of nonalcoholic fatty liver disease and advanced fibrosis in a Texas Hispanic community cohort
	Pan JJ1, Fisher-Hoch SP1, Chen C1, Feldstein AE1, McCormick JB1, Rahbar MH1, Beretta L1, Fallon MB1. World J Hepatol. 2015 Jun 18;7(11):1586-94. doi: 10.4254/wjh.v7.i11.1586.

85.	Dysregulated Hepatic Methionine Metabolism Drives Homocysteine Elevation in Diet-Induced Nonalcoholic Fatty Liver Disease
	Pacana T1, Cazanave S1, Verdianelli A1, Patel V1, Min HK1, Mirshahi F1, Quinlivan E2, Sanyal AJ1. PLoS One. 2015 Aug 31;10(8):e0136822. doi: 10.1371/journal.pone.0136822. eCollection 2015.

86.	Cost-Effective Evaluation of Nonalcoholic Fatty Liver Disease With NAFLD Fibrosis Score and Vibration Controlled Transient Elastography
	Tapper EB1, Sengupta N1, Hunink MG2,3, Afdhal NH1, Lai M1. Am J Gastroenterol. 2015 Sep;110(9):1298-304. doi: 10.1038/ajg.2015.241. Epub 2015 Aug 25.

87.	Nonmedicinal interventions in nonalcoholic fatty liver disease
	Neuman MG, Nanau RM, Cohen LB. Can J Gastroenterol Hepatol. 2015 Jun-Jul;29(5):241-52.

88.	Non-alcoholic fatty liver disease following liver transplantation: a clinical review
	Merola J1, Liapakis A2, Mulligan DC1, Yoo PS1. Clin Transplant. 2015 Sep;29(9):728-37. doi: 10.1111/ctr.12585. Epub 2015 Aug 11.

89.	Vitamin E has a beneficial effect on nonalcoholic fatty liver disease: a meta-analysis of randomized controlled trials
	Sato K1, Gosho M2, Yamamoto T3, Kobayashi Y3, Ishii N3, Ohashi T3, Nakade Y3, Ito K3, Fukuzawa Y3, Yoneda M3. Nutrition. 2015 Jul-Aug;31(7-8):923-30. doi: 10.1016/j.nut.2014.11.018. Epub 2014 Dec 24.

90.	Noninvasive Assessment of Fibrosis in Patients with Nonalcoholic Fatty Liver Disease
	Buzzetti E1, Lombardi R1, De Luca L1, Tsochatzis EA1. Int J Endocrinol. 2015;2015:343828. doi: 10.1155/2015/343828. Epub 2015 Apr 30.

91.	Bile Acid Signaling: Mechanism for Bariatric Surgery, Cure for NASH?
	Kohli R1, Myronovych A, Tan BK, Salazar-Gonzalez RM, Miles L, Zhang W, Oehrle M, Sandoval DA, Ryan KK, Seeley RJ, Setchell KD. Dig Dis. 2015;33(3):440-6. doi: 10.1159/000371699. Epub 2015 May 27.

92.	Trends in the Burden of Non-alcoholic Fatty Liver Disease in a US Cohort of Veterans
	Kanwal F1, Kramer JR2, Duan Z2, Yu X3, White D4, El-Serag HB5. Clin Gastroenterol Hepatol. 2015 Aug 17. pii: S1542-3565(15)01109-X. doi: 10.1016/j.cgh.2015.08.010. [Epub ahead of print]

93.	Hepatocellular Carcinoma in the Setting of Non-cirrhotic Nonalcoholic Fatty Liver Disease and the Metabolic Syndrome: US Experience.
	Perumpail RB1, Wong RJ, Ahmed A, Harrison SA. Dig Dis Sci. 2015 Aug 7. [Epub ahead of print]

94.	Weight Loss Through Lifestyle Modification Significantly Reduces Features of Nonalcoholic Steatohepatitis.
	Vilar-Gomez E1, Martinez-Perez Y2, Calzadilla-Bertot L2, Torres-Gonzalez A2, Gra-Oramas B3, Gonzalez-Fabian L3, Friedman SL4, Diago M5, Romero-Gomez M6. Gastroenterology. 2015 Aug;149(2):367-378.e5. doi: 10.1053/j.gastro.2015.04.005. Epub 2015 Apr 10.

95.	Association of Non-alcoholic Fatty Liver Disease (NAFLD) with Hepatocellular Carcinoma (HCC) in the United States from 2004-2009
	Younossi ZM1,2,3, Otgonsuren M3, Henry L1,3, Venkatesan C2, Mishra A1, Erario M2, Hunt S1. Hepatology. 2015 Aug 14. doi: 10.1002/hep.28123. [Epub ahead of print]

96.	NAFLD Review: Diagnosis, Treatment and Outcomes
	Ahmed A1, Wong RJ2, Harrison SA3. Clin Gastroenterol Hepatol. 2015 Jul 27. pii: S1542-3565(15)00988-X. doi: 10.1016/j.cgh.2015.07.029. [Epub ahead of print]